Kihealth Labs

Publication center

Open science is part of our operating model.

Browse and search every peer-reviewed paper, conference abstract, scientific poster, white paper, and patent published by the Kihealth Labs scientific team.

Publication center

A searchable library of our science.

Peer-reviewed publications, conference abstracts, scientific posters, white papers, and granted intellectual property — across every InterceptIQ™ program.

23 assets indexed
Search
23 resultsUpdated weekly · v2026.06
Publications
PUB-26-01
2026
BetaIntercept™ T1
Nature Medicine

Methylation-resolved cell-free DNA detects pre-clinical β-cell death in autoantibody-positive children

Chen S, Okafor A, Müller-Lindqvist E, et al.

Methylationdoi:10.1038/s41591-026-0142-x
87.2
Impact
24
Cites
Publications
PUB-26-02
2026
Platform
Cell

A federated atlas of tissue-of-origin signal in circulating cell-free DNA

Park J, Khoury N, Vásquez R, et al.

Machine Learningdoi:10.1016/j.cell.2026.03.011
64.5
Impact
41
Cites
Abstracts
ABS-26-ADA
2026
BetaIntercept™ T1
ADA Scientific Sessions 2026

Plasma INS-promoter methylation predicts time-to-clinical T1D in TrialNet at-risk cohort

Chen S, Imani D, et al.

Clinical
2
Pages
Posters
POS-26-KEY
2026
Platform
Keystone — Liquid Biopsy

Analytical validation of the InterceptIQ™ cfDNA assay across three CLIA sites

Kihealth Analytical Validation Team

Chemistry
White papers
WP-26-001
2026
Platform
Kihealth Labs

InterceptIQ™ Platform Architecture — Technical Overview v2

Office of the CTO

Machine Learning
34
Pages
Publications
PUB-25-04
2025
OncoIntercept™
New England Journal of Medicine

Prospective surveillance of high-risk pancreatic cohorts using cfDNA fragmentomics

Tanaka H, Reilly C, Mancuso F, et al.

Fragmentomicsdoi:10.1056/NEJMoa2509921
158.5
Impact
112
Cites
Publications
PUB-25-09
2025
Platform
Nature Biotechnology

InterceptIQ™: a multi-task deep learning framework for cell-free DNA diagnostics

Singh R, Park J, Chen S, et al.

Machine Learningdoi:10.1038/s41587-025-02114-2
68.2
Impact
76
Cites
Abstracts
ABS-25-ASCO
2025
OncoIntercept™
ASCO Annual Meeting 2025

Tumor-naive MRD detection across CRC, NSCLC, and breast cohorts (n=1,120)

Vásquez R, Hassan A, et al.

Clinical
2
Pages
Abstracts
ABS-25-AAIC
2025
NeuroIntercept™
AAIC 2025

Cortical-neuron cfDNA distinguishes prodromal AD from age-matched controls

Khoury N, Park J, et al.

Methylation
2
Pages
Posters
POS-25-EASD
2025
BetaIntercept™ T2
EASD 2025

Multi-tissue methylation atlas applied to T2D metabolic staging

Reilly C, et al.

Methylation
Posters
POS-25-AGBT
2025
Platform
AGBT 2025

Low-input bisulfite library chemistry — 1 ng plasma input

Khoury N, et al.

Chemistry
White papers
WP-25-004
2025
Platform
Kihealth Labs

Tissue-of-origin inference: methods, limits, and clinical validation

Computational Biology

Methylation
22
Pages
White papers
WP-25-002
2025
Platform
Kihealth Labs

Pre-analytical handling for cfDNA: stability, recovery, and contamination control

Wet Lab Operations

Chemistry
18
Pages
Patents
US-11,842,901
2025
BetaIntercept™ T1
USPTO — Granted

Compositions and methods for methylation-specific detection of β-cell-derived cfDNA

Chen S, Park J, Singh R

IPUSEUJPCN
Patents
US-11,901,332
2025
OncoIntercept™
USPTO — Granted

Fragmentomic end-motif models for low tumor-fraction cancer detection

Okafor A, Singh R

IPUSEUCN
Patents
US-2025/0114287
2025
Platform
USPTO — Published

Tissue-of-origin inference from methylation atlas with 47-cell-type resolution

Ramirez D, Park J

IPUSEUJPAU
Publications
PUB-24-11
2024
Platform
Nature Genetics

End-motif and fragment-length signatures encode chromatin-state biology in plasma

Okafor A, Park J, et al.

Fragmentomicsdoi:10.1038/s41588-024-01789-3
33.1
Impact
58
Cites
Publications
PUB-24-07
2024
BetaIntercept™ T2
Cell Metabolism

Hepatocyte cfDNA dynamics during metabolic disease progression

Reilly C, Müller-Lindqvist E, et al.

cfDNAdoi:10.1016/j.cmet.2024.08.004
31.4
Impact
39
Cites
Abstracts
ABS-24-AACR
2024
OncoIntercept™
AACR Annual Meeting 2024

Low tumor-fraction detection at VAF 0.005% using fragmentomic priors

Hassan A, Wu L, et al.

Fragmentomics
1
Pages
Posters
POS-24-SITC
2024
OncoIntercept™
SITC 2024

Pharmacodynamic cfDNA readout in IO combination trials

Hassan A, et al.

Clinical
White papers
WP-24-007
2024
Platform
Kihealth Labs

Federated learning across nine medical centers — system design

Infrastructure Engineering

Machine Learning
27
Pages
Patents
WO-2024/118832
2024
Platform
WIPO — Published

Federated training systems for clinical cfDNA models without data egress

Wu L, Singh R, Park J

IPUSEU
Patents
WO-2024/091104
2024
Platform
WIPO — Published

Low-input bisulfite library construction for plasma cfDNA

Khoury N, Tanaka H

IPUSEUUK

Restricted assets are available under NDA — research@kihealthlabs.com